Today, NNE published its Annual Report 2025, marking a year defined by strong execution, continued growth and record‑high activity levels across the organisation.
In 2025, NNE delivered on its strategy by executing the largest pharma project portfolio in the company’s history, including some of the most complex pharma projects ever undertaken. The scale and scope of this execution are reflected in the financial results, with sales increasing by 16% to more than DKK 4,500 million and an operating profit margin of 12%.
Commenting on the results, Christoffer Hviid, Chief Financial Officer at NNE, says:
“These strong results were made possible by the dedication and expertise of our colleagues across the organisation, combined with strong collaboration with our customers. I would like to say a huge thank you to everyone at NNE for their strong commitment throughout 2025.”
The Annual Report 2025 provides a comprehensive overview of NNE’s performance and progress during the year.
Watch the video down below to see our highlights or explore the full report.
